MONO-SIALO GANGLIOSID GM1P, PRAEPARATER INDEHOLDENDE DETTE SAMT ANVENDELSE DERAF TIL FREMSTILLING AF ET LAEGEMIDDEL

A novel mono-sialo ganglioside derivative substantially identical chemically and physically with a product prepared by(a) concentration of an aqueous solution of a mono-sialo ganglioside and clacium ions under sub-atmospheric pressure at 40-80°C for 18-240 hours,(b) adjustment of the pH to 2-3, foll...

Full description

Saved in:
Bibliographic Details
Main Authors CAVALLO, GIOVANNI, TUBARO, EZIO
Format Patent
LanguageDanish
Published 19.07.1993
Edition5
Subjects
CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SUGARS
Online AccessGet full text

Cover

More Information
Summary:A novel mono-sialo ganglioside derivative substantially identical chemically and physically with a product prepared by(a) concentration of an aqueous solution of a mono-sialo ganglioside and clacium ions under sub-atmospheric pressure at 40-80°C for 18-240 hours,(b) adjustment of the pH to 2-3, followed by dialysis, and(c) evaporation of the aqueous solvent.The novel ganglioside is believed to be a new physical form of the known ganglioside GM1 and shows activity against bacteria, viruses, protozoal, fungi and tumours. It has previously been suggested that gangliosides in general may be useful in the treatment of neurological disorders but not that they affect the activity of phagocytes.
Bibliography:Application Number: DK19840003569